ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial

Future Oncology, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2tbCoAe
via IFTTT